KING OF PRUSSIA, Pa., May 20, 2014 /PRNewswire/ -- People managing primary immunodeficiency (PI) with CSL Behring's Hizentra ® (Immune Globulin Subcutaneous [Human]) may now be eligible for financial support through the Hizentra ® Co-Pay Relief Program. The new program offers eligible U.S. patients up to $4,000 per year to be applied toward Hizentraco-payments, deductibles and coinsurance. Out-of-pocket therapy costs will be processed seamlessly through the electronic billing systems of specialty pharmacies and physician offices, which means no paperwork is required for the patient, pharmacist or physician.
"CSL Behring is committed to providing medical innovations and supportive services that make a meaningful difference in the lives of people living with a serious health condition," said Lynne Powell, Senior Vice President, North America Commercial Operations, CSL Behring. "The Hizentra Co-Pay Relief Program is another example of this commitment and was designed to specifically meet the needs of the primary immunodeficiency community by increasing access to Hizentra." Enrollment in the Hizentra Co-Pay Relief Program is automated and paperless, and members can access their account online at any time. Patients can contact CSL Behring's IgIQ resource center at 1-877-355-IGIQ (4447) to confirm eligibility and to discuss the steps for enrolling. The program is open to U.S. residents who are at least 2 years old and diagnosed with PI. Participants must have U.S.-based private insurance that covers Hizentra. Individuals covered by state- or federally funded programs, such as Medicare, Medicare Advantage plans, Medicaid, PCIP, Champus, TriCare, and Veterans Administration (VA), are not eligible. "For many of the 250,000 people in the U.S. diagnosed with a primary immunodeficiency, immunoglobulin replacement therapy is an essential part of staying healthy," said Marcia Boyle, President and Founder of the Immune Deficiency Foundation. "We applaud CSL Behring for the company's long-standing commitment to the PI community and now for the Hizentra Co-Pay Relief Program, which will make a meaningful difference to those taking CSL Behring's subcutaneous immunoglobulin." For more information about the Hizentra Co-Pay Relief Program, please call 1-877-355-IGIQ (4447) or visit www.Hizentra.com/copay. About Primary Immunodeficiencies More than 200 types of PIs are recognized by the World Health Organization. For individuals with PI, many of them children, infections may not improve as expected with usual treatments and may even keep returning. As a result, patients may face repeated rounds of antibiotics or hospitalization for treatment. Repeated infections can lead to organ damage, which over time can become life-threatening. Some infections, such as meningitis, can even result in death.